


CONTACT INFORMATION: **Elana Holzman** Tel +972-3-926-7554, E-mail: elana.holzman@teva.co.il **Kevin Mannix** Tel (215) 591-8912, E-mail: kevin.mannix@tevausa.com

Company Overview


Teva Pharmaceutical Industries Ltd., is among the top 15 pharmaceutical companies in the world and the leader in generic pharmaceuticals, specializing in development, production and marketing of a wide range of generic, innovative and branded pharmaceuticals, biogenerics and active pharmaceutical ingredients. Teva currently operates in over 60 countries with some 35,000 employees worldwide. Its innovative R&D efforts focus on therapies for the central nervous system (with emphasis

on multiple sclerosis), autoimmune diseases and oncology. Teva differentiates itself by balancing its portfolio with generic, innovative and branded products, vertically integrating its pharmaceutical and API activities, combining local customer responsiveness with a "global edge", and by its global footprint. Teva's success lies in the leadership of its management, the skills and devotion of its people, the quality of its offerings and its focus on customers and patients.


Net Sales (U.S. \$ in Millions)



Net Income^(1,2) (U.S. \$ in Millions)



Earning Per Share^(1,2) (U.S. \$)




Market Data (As of May 3, 2010)

Stock Symbol	TEVA
Closing Price	\$60.03
52 Week Range	\$43.32 - \$64.95
Market Capitalization	\$53.66 billion
#12 in NASDAQ-100	


NASDAQ-100



Stock Chart (As of May 3, 2010)



R&D Expenses (net) (U.S. \$ in Millions)



(1) Reflects non-GAAP results. (2) Reflects retroactive adjustment following the adoption of APB14-1.

Recent Events

April 7, 2010 - The FDA has granted final approval for Teva's generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium). As the first company to file ANDAs that contained a paragraph IV certification for Hyzaar® and Cozaar®, Teva has been awarded 180-day Hatch-Waxman statutory exclusivity to market these products. The brand products had combined annual sales of approximately \$1.6 billion in the United States, based on IMS sales data.

April 1, 2010 - The U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Teva Women's Health, brought suit against Watson alleging infringement of Teva's patent as a result of Watson's filing of an ANDA for Seasonique®. The ANDA sought approval to market a generic version of Seasonique in the U.S. before the patent expires on January 30, 2024.

April 1, 2010 - Teva announced that the patent infringement litigation pertaining to its generic version of sanofi-aventis and Debiopharm's Eloxatin (oxaliplatin injection) has been dismissed by the United States District Court for the District of New Jersey pursuant to a settlement between the parties. The settlement includes an injunction prohibiting Teva from selling its oxaliplatin injection product and a license to reenter the market at a later

point in time.

March 18, 2010 - Teva announced a definitive agreement to acquire ratiopharm, Germany's second largest generics producer, for an enterprise value of €3.625 billion. The acquisition will position Teva as the leading generic pharmaceutical company in Europe, increasing its European business from sales of \$3.3 billion in 2009 to joint pro forma sales of \$5.2 billion. The transaction is subject to certain conditions including relevant regulatory approvals, and is expected to close by the end of 2010.


March 9, 2010 - Teva's Board of Directors received a letter from Mr. Eli Hurvitz indicating that he wishes to be released from his duties at Teva. The Board has thus unanimously appointed its Vice Chairman, Dr. Phillip Frost, to serve as Chairman of the Board of Directors. Dr. Phillip Frost (73) has served as Vice Chairman of the Board of Directors of Teva since January 2006, following the acquisition of Ivax Corporation by Teva.

February 8, 2010 - Teva and Active Biotech announced that they have amended the marketing and distribution agreement for oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis. Under the new agreement, Teva extended its marketing and distribution rights to include the Nordic and Baltic regions. Active Biotech will receive a higher royalty rate for sales in these territories.

Sales by Region

Q1/10: \$3.7 billion


North America	63%
Europe(1)	22%
Latin America(2)	5%
Israel	4%
CEE	4%
ROW	2%



(1) Includes EU member states, Switzerland & Norway

(2) Includes Mexico

COPAXONE® - Global in-Market Sales (U.S. \$ in Millions)



U.S. Generic Pipeline (As of April 26, 2010)

210 ANDAs -
Over \$113 billion in total branded sales
133 Paragraph IV Filings
83 First-To-File

Over \$50 Billion In Total Branded Sales

Proprietary Branded Pharmaceuticals - Pipeline

Marketed products	End of Phase III 2010-2012	End of Phase III 2013-2015
Copaxone® Multiple Sclerosis	Laquinimod - Oral Multiple Sclerosis (Phase III)	TV-1101 (OGX-011) Solid Tumors (Phase III)
Azilect® Parkinson's	StemEx® - Hemato-oncological (Phase III)	DiaPep-277 - Type I Diabetes (Phase III)
QVAR® Inhaled Steroid	Debrase - Burns (Phase III)	Laquinimod - Crohn's disease (Phase II)
ProAir® Inhaled short acting beta-mimetic	Pagoclone - Stuttering (Phase II)	CT-011 - Hemato-Oncological (Phase II)
Easi-Breathe products Asthma & COPD	Talampanel - ALS (Phase II)	CT-011 - Solid Tumor Oncology (Phase II)
Seasonique® / LoSeasonique-Extended Regimen Contraception	BDP HFA Nasal - Respiratory (Phase III)	Laquinimod - Lupus (Phase I)
Plan B® One-Step Emergency Contraception	4 Respiratory projects (undisclosed)	TV-1390 - Multiple Sclerosis (Phase III)
ParaGard® Intrauterine Contraception	DR-103 - Contraception (Phase III)	2 Respiratory projects (undisclosed)
Enjuvia® Hormone Therapy	Oxybutynin Vaginal Ring - Overactive Bladder (Phase III)	2 Biosimilars projects (undisclosed)
TEV-TROPIN® Growth Hormone Deficiency	Progesterone Vaginal Ring - Infertility (Phase III)	
TevaGrastim®/Neurotral Hematology	DR-102 Contraception (Phase III)	
	Neugranin - Hematology (Phase II)	

Selected Generic Approvals U.S (January 2010 - April 2010)

Product		Approval/ Launch Date	Branded Product		Indication
			Name	Market size (U.S. \$ in Millions)	
Letrozole Tablets ⁽³⁾	Tablets	20/01/10	Femara®	585	Breast cancer treatment
Temozolomide ⁽²⁾	Capsules	01/03/10	Temodar®	371	Treatment of glioblastoma multiforme and anaplastic astrocytoma
Memantine HCl ⁽²⁾ shared ⁽³⁾	Tablets	19/03/10	Namenda®	1,172	Treatment of dementia of the Alzheimer's type
Abacavir/Lamivudine ⁽²⁾⁽³⁾	Tablets	29/03/10	Epzicom®	414	Treatment of HIV
Losartan Potassium ⁽¹⁾⁽²⁾	Tablets	06/04/10	Cozaar®	959	Treatment of hypertension
Losartan Potassium/HCTZ ⁽¹⁾⁽²⁾	Tablets	06/04/10	Hyzaar®	695	Treatment of hypertension

(1) Launched (2) Exclusivity (180 days) (3) Tentative approval